KALY – Kali Extracts Confirms Analyst Report On Cannabis Extract Biopharmaceutical Strategy Scheduled For Publication Next Week



DALLAS, Aug. 23, 2019– — Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today confirmed the publication of an analyst report covering the company’s overall cannabis extract biopharmaceutical strategy is scheduled for next week on Wednesday, August 28, 2019. After making a strategic acquisition in Q4 2018 of a business with a U.S. Patented Cannabis Extraction Process, KALY has just posted its 2019 YTD financials reporting 250% revenue growth. The company has also this week filed for a new patent for a CBD Formulation for the treatment of Chronic Obstructive Pulmonary Disease (COPD). The CBD Formulation brand name is RespRx ( In light of the recent updates, ongoing analyst coverage will be updated with a new report scheduled for publication on Wednesday next week.

To learn more about the company visit

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company’s actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.

Frederick Ferri
(214) 210-0459


Mcap MediaWire - Costumer Service

Translate »